Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR), a clinical-stage biopharmaceutical company, rocketed 237.5% higher in 2018, according to data from S&P Global Market Intelligence. The stock began the year under pressure, but recovered in a big way thanks to a growing pipeline of early stage RNA interference drugs.